Last €304.00 EUR
Change Today +4.00 / 1.33%
Volume 50.0
RGO On Other Exchanges
As of 2:57 AM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (RGO) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/23/14 - €304.00
52 Week Low
12/18/13 - €189.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

regeneron pharmaceuticals (RGO) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company’s antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.

2,469 Employees
Last Reported Date: 08/5/14
Founded in 1988

regeneron pharmaceuticals (RGO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $194.2K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $2.6M
Senior Vice President of Research & Developme...
Total Annual Compensation: $863.0K
Senior Vice President of Commercial
Total Annual Compensation: $814.5K
Compensation as of Fiscal Year 2013.

regeneron pharmaceuticals (RGO) Key Developments

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks. Secondary objectives of the study will evaluate the long-term safety and efficacy of dupilumab up to 52 weeks. The trial will enroll approximately 700 adult patients. The LIBERTY AD Phase 3 clinical program will consist of at least five trials of patients with moderate-to-severe AD at sites worldwide.

Amgen Files Lawsuit Against Sanofi, Aventisub LLC and Regeneron Pharmaceuticals, Inc. for Patent Infringement

Amgen announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively Sanofi), and Regeneron Pharmaceuticals, Inc. (Regeneron) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S.

Regeneron Pharmaceuticals, Inc. Announces Executive Appointments

Regeneron Pharmaceuticals, Inc. announced the appointment of Alan Shuldiner, M.D., as the Vice President of Translational Genetics. Dr. Shuldiner joins Regeneron from the University of Maryland School of Medicine where he served as the Division Head of Endocrinology, Diabetes and Nutrition and Associate Dean and Director of the Program for Personalized and Genomic Medicine. The RGC has also named Richard Lifton, M.D., Ph.D., as Chairman of its new Scientific Advisory Board. Dr. Lifton is currently the Sterling Professor of Genetics, Professor of Medicine (Nephrology), and Chairman of the Department of Genetics at Yale University, as well as an investigator at the Howard Hughes Medical Institute.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €304.00 EUR +4.00

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $173.27 USD -1.20
Allergan Inc/United States $182.81 USD -3.35
BioMarin Pharmaceutical Inc $74.32 USD -0.39
UCB SA €66.25 EUR +0.49
Vertex Pharmaceuticals Inc $106.17 USD -1.99
View Industry Companies

Industry Analysis


Industry Average

Valuation RGO Industry Range
Price/Earnings 100.0x
Price/Sales 15.3x
Price/Book 16.1x
Price/Cash Flow 97.2x
TEV/Sales 14.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at